Late breaking abstract to provide new updates from THIO-101 Phase 2 clinical trial in non-small cell lung cancer (NSCLC) Poster to highlight long-term therapeutic benefits of THIO sequenced with ...
THIO combined with Libtayo shows improved progression-free survival of 5.6 months versus 2.5 months with standard treatments in advanced non-small cell lung cancer. The THIO-101 trial indicates a ...
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer ...
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results